Highest-materiality recent filing
Annual base salary of $260,000 for new CFO Sigal Fattal, plus customary social benefits.
Chemomab appoints Adi Mor CEO, Sigal Fattal CFO; extends cash runway to end of 2024
Adi Mor, co-founder and CSO, reappointed CEO effective June 1, 2023, replacing Dale Pfost.
Chemomab Q1 net loss $8.8M; cash $32.8M; CM-101 Phase 2 NASH trial meets safety endpoint
Net loss of $8.8M ($0.04 per share) vs $5.1M in Q1 2022; R&D expenses rose to $6.9M from $2.7M.
Chemomab reports FY2022 net loss of $27.6M; cash runway through March 2024
Net loss of $27.6M in 2022 vs $12.5M in 2021; R&D expenses rose 168% to $17.0M.
Chemomab receives FDA clearance to start Phase 2 trial of CM-101 in systemic sclerosis
FDA cleared IND for Phase 2 ABATE trial of CM-101 in systemic sclerosis (SSc).
Chemomab Therapeutics filed an updated corporate presentation on January 11, 2023.
Trial met primary endpoint: safety and tolerability; no significant injection site reactions, no anti-drug antibodies.
Chemomab appoints Matthew Frankel as Chief Medical Officer & VP Drug Development
Start Date November 14, 2022; report to Chairman & CEO Dale Pfost.
Israeli court approves Chemomab repurchase of 582,023 ADSs from co-founders
Approved repurchase of up to 582,023 ADSs for approx. $1,213,400 to help co-founders pay tax.
Chemomab appoints Matthew Frankel as CMO & VP Drug Development, effective Nov 14
Dr. Frankel will receive annual base salary of $450,000 and bonus potential of 45% of base.
Chemomab Q2 net loss $6.2M, cash $51.8M; NASH topline due by year-end
Net loss $6.2M ($0.03/share) for Q2 2022 vs $2.8M loss in Q2 2021; R&D expense rose to $2.9M from $1.3M.
Chemomab appoints Jill M. Quigley to board of directors
Jill M. Quigley appointed to Chemomab board and audit committee, effective June 16, 2022.
Chemomab reports 2022 Annual Meeting vote results; all proposals pass
Proposal 1: re-elect Dr. Nissim Darvish as Class I director received 84,055,680 FOR, 591,060 AGAINST.
Chemomab Director Joel Maryles to step down at 2022 AGM
Joel Maryles, Class I director, notified Chemomab on May 31, 2022 he will not seek re-election.
Chemomab Q1 net loss $5.1M; cash $57.5M; advancing CM-101 in PSC and SSc
Net loss of $5.1M ($0.02 per share) vs $1.7M in Q1 2021; R&D expenses $2.7M, G&A $2.6M (incl $0.9M stock comp).
Net loss $12.5M ($0.06 per share) in FY2021 vs $6.0M in FY2020; cash $61.2M at Dec 31, 2021.
Chemomab shareholders approve CEO Dale Pfost as Chairman of the Board
Special meeting on Feb 10, 2022; 89,749,560 shares represented (~39.35% of outstanding).
Stephen Squinto resigns as chairman and director effective Dec 19, 2021; decision not due to any disagreement with company.
Chemomab CMO Aharon resigns; Weiner appointed Interim CMO
Dr. Arnon Aharon resigned as CMO effective Feb 1, 2022; will continue 60 days and as senior advisor.
Chemomab appoints Donald Marvin as CFO & COO, replacing Sigal Fattal effective Nov 8, 2021
Sigal Fattal's engagement as interim CFO concluded by mutual agreement; she remains as senior consultant.
Chemomab reports Q3 net loss of $3.0M; cash $64.3M; appoints new CEO and CFO
Cash and equivalents $64.3M as of Sept 30, 2021; expected to fund operations to mid-2023.
Chemomab Therapeutics files updated corporate presentation on November 10, 2021
Filed Form 8-K on Nov 10, 2021, including Items 7.01 (Regulation FD) and 9.01 (Exhibits).
Chemomab names Donald Marvin CFO, EVP & COO; outgoing interim CFO stays as advisor
Donald Marvin appointed CFO, EVP, and COO effective November 8, 2021.
Chemomab Therapeutics files updated corporate presentation on systemic sclerosis
Presentation dated November 3, 2021, focuses on systemic sclerosis (SSc) program.
Chemomab shareholders approve CEO Dale Pfost employment terms at special meeting
Special meeting held Oct 25, 2021; 42.74% of outstanding shares represented.
Chemomab Therapeutics files updated corporate presentation for October 2021
Filed an updated corporate presentation covering its fibrotic disease pipeline.
Chemomab appoints Dale Pfost as CEO; co-founder Adi Mor becomes CSO
Dr. Dale Pfost appointed CEO, subject to shareholder approval expected Q4 2021.
Chemomab Q2 net loss $2.8M; cash $67M; Phase 2 trials on track for 2022 data
Net loss $2.8M ($0.01 per share) vs $1.1M loss in Q2 2020; R&D expenses $1.3M (up from $0.8M).
Proposal 1: Compensation Policy approved with 103,259,980 votes for (99.5%), meeting Israeli Companies Law requirements for non-controlling shareholders.
In connection with his replacement as Chief Executive Officer, on June 1, 2023, Dr. Dale Pfost agreed to step down from his position on the Board, including in his capacity as Chairman of the Board, effective as of the same date.
appointed Dr. Adi Mor, co-founder of the Company, a current class III member of the Board and the Company's Chief Scientific Officer, as Chief Executive Officer of the Company to replace Dr. Dale Pfost, effective as of the same date.
the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.
the Board appointed Ms. Sigal Fattal, the VP of Finance of the Company, as the Chief Financial Officer of the Company to replace Mr. Donald Marvin, effective as of the same date.
On November 14, 2022, Chemomab Therapeutics Ltd. (the “Company”) announced the appointment of Dr. Matthew B. Frankel as Chief Medical Officer & VP, Drug Development of the Company.
appointed Jill M. Quigley to the Board and the audit committee of the Board (the “Audit Committee”), effective immediately.
On May 31, 2022, Joel Maryles, a member of the Board of Directors (the “Board”) of Chemomab Therapeutics Ltd. (the “Company”), notified the Company that he will not stand for re-election at the Company’s 2022 Annual General Meeting of shareholders, to be held on June 7, 2022, and, accordingly, Mr. Maryles’ term as a Class I director will expire at the 2022 Annual General Meeting.
On December 12, 2021, the Company and Mr. Squinto mutually agreed that Mr. Squinto’s resignation as the chairman of the Board will enter into effect on December 19, 2021.
the nominating and governance committee and the Board each approved and recommended that the shareholders approve the appointment of Dr. Pfost as chairman of the Board.
On November 29, 2021, Dr. Arnon Aharon notified Chemomab Therapeutics Ltd. (the “Company”) of his resignation as its Chief Medical Officer, which will enter into effect on February 1, 2022.
it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.
On November 8, 2021, the Company issued a press release announcing that, on November 8, 2021, it appointed Mr. Donald Marvin as the Chief Financial Officer, Executive Vice President and Chief Operating Officer of the Company, effective as of November 8, 2021.
Max materiality 0.80 · Median 0.55 · Most common event leadership